# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)

> **NCT02414594** · PHASE1 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Elevated Lipoprotein(a)

## Interventions

- **DRUG:** IONIS-APO(a)-LRx
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT02414594
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414594, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02414594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*